Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Astellas to Sell 3 Asian Products to Daiichi Sankyo for 9.6 Billion Yen
October 16, 2019
- FDA OKs 1st Schizophrenia Patch Drug: Hisamitsu
October 16, 2019
- Eisai’s Fycompa Gets China Thumbs-Up
October 16, 2019
- No Major Drug Supply Disruption after Typhoon Hagibis
October 16, 2019
- Sakigake-Designated Radiation Therapy Agent Filed in Japan
October 16, 2019
- OrphanPacific to Take Over Marketing Authorization for MSD’s Diazoxide
October 16, 2019
- Sanofi, Kaken to Wind Up Clexane Partnership
October 16, 2019
- Eyes Turn to SGLT2 Inhibitors after Entresto’s Narrow Miss in HFpEF
October 16, 2019
- AZ, Sanofi Kick Off Japan PIII for RSV Prevention
October 15, 2019
- MSD Seeking to Trim 250 Jobs in Japan
October 15, 2019
- Japan Ethical Drug Market Forecast at 8.9 Trillion Yen in 2026: Fuji Keizai
October 15, 2019
- Shionogi Signs New Mycobacterial Deal with Hsiri
October 15, 2019
- GSK Japan to Pull Prescribed Zantac and Compensate for Substitutes; Generic Peers Follow
October 11, 2019
- All Eyes on Performance of Top-2 Anti-Flu Drugs Xofluza, Inavir as Flu Seasons Approaches
October 11, 2019
- Daiichi Sankyo’s AML Drug Vanflyta Now Available
October 11, 2019
- AZ, Keio Univ. Pair Up to Create Real World Evidence in Healthcare
October 11, 2019
- GSK Japan Ups Recall Level for Zantac to “Class I”
October 10, 2019
- Sosei Bags US$3 Million from Genentech on Nomination of New GPCR Disease Target
October 10, 2019
- Mitsubishi Tanabe Gains Japan, Asian Rights for Viela Bio's Inebilizumab
October 10, 2019
- Meiji to Strengthen Contract Manufacturing, Aims to Produce 3 Billion Tablets Annually for Japan Market
October 10, 2019
ページ
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…